Lucosky Brookman Serves as Counsel to NanoViricides in Closing of $6 Million Registered Direct Offering and Concurrent Private Placement

NanoViricides, Inc. (NYSE American: NNVC) announced the successful closing of its previously announced registered direct offering with a single healthcare institutional investor. The Company sold 3,571,429 shares of common stock (or common stock equivalents) at a purchase price of $1.68 per share, generating gross proceeds of approximately $6 million.

In a concurrent private placement, NanoViricides issued Series A warrants to purchase up to 3,571,429 shares of common stock and Series B warrants to purchase an additional 3,571,429 shares. The Series A Warrants are exercisable after six months, carry an exercise price of $1.75 per share, and expire two years after issuance. The Series B Warrants, which reflect roughly a 20% premium to the Company’s November 10, 2025 closing share price, are exercisable after six months at $2.00 per share and expire 5.5 years from issuance.

NanoViricides intends to use the net proceeds from the Offering for working capital and general corporate purposes.

A.G.P./Alliance Global Partners served as the sole placement agent for the transaction.Lucosky Brookman LLP served as counsel to NanoViricides, Inc. in connection with the Offering.